All In Biotech

Drug Trial Radar · NCT03497897

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

66

Actual

Start

Sep 10, 2018

Primary completion

Feb 24, 2022

Study completion Mar 9, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.

Conditions

  • Inflammatory Acne

Interventions

  • LYS006 20 mgDrug

    LYS006 20 mg, capsules, oral administration, BID, for 12 weeks

  • LYS006 2 mgDrug

    LYS006 2 mg, capsules, oral administration, BID, for 12 weeks

  • PlaceboDrug

    Matching placebo, capsules, oral administration, BID, for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Inflammatory Lesion CountTime frame: Week 12

Locations

17 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Fremont, California

  • Novartis Investigative Site

    Santa Monica, California

  • Novartis Investigative Site

    Hialeah, Florida

  • Novartis Investigative Site

    New Orleans, Louisiana

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Pflugerville, Texas

  • Novartis Investigative Site

    Pilsen, Czechia

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Bad Bentheim, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Szeged, Hungary

  • Novartis Investigative Site

    Nijmegen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.